Insider Selling: DexCom (NASDAQ:DXCM) EVP Sells 4,912 Shares of Stock

DexCom, Inc. (NASDAQ:DXCM) EVP Jon Coleman sold 4,912 shares of the stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $73.00, for a total transaction of $358,576.00. Following the sale, the executive vice president owned 100,361 shares of the company’s stock, valued at $7,326,353. This trade represents a 4.67% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jon Coleman also recently made the following trade(s):

• On Thursday, June 4th, Jon Coleman sold 4,911 shares of DexCom stock. The shares were sold at an average price of $74.13, for a total value of $364,052.43.

DexCom Stock Performance

DexCom stock traded up $0.27 during mid-day trading on Friday, reaching $72.86. 4,672,514 shares of the company were exchanged, compared to its average volume of 5,348,739. The firm’s 50-day simple moving average is $64.71 and its two-hundred day simple moving average is $66.94. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $89.98. The firm has a market cap of $28.11 billion, a PE ratio of 31.14, a price-to-earnings-growth ratio of 1.14 and a beta of 1.45. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.64 and a current ratio of 1.95.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The business had revenue of $1.19 billion during the quarter, compared to analysts’ expectations of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.32 earnings per share. Equities analysts predict that DexCom, Inc. will post 2.57 earnings per share for the current fiscal year.

Institutional Trading of DexCom

Institutional investors have recently bought and sold shares of the company. Reflection Asset Management acquired a new stake in DexCom in the fourth quarter valued at $25,000. Ascentis Independent Advisors acquired a new stake in DexCom in the 1st quarter valued at about $25,000. CVA Family Office LLC increased its holdings in DexCom by 48.5% during the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 147 shares in the last quarter. MCF Advisors LLC acquired a new position in DexCom during the fourth quarter worth about $32,000. Finally, ORG Partners LLC raised its position in DexCom by 124.3% during the fourth quarter. ORG Partners LLC now owns 507 shares of the medical device company’s stock worth $34,000 after acquiring an additional 281 shares during the last quarter. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on DXCM shares. Wells Fargo & Company cut their price target on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating for the company in a report on Friday, February 13th. Wall Street Zen cut DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 10th. TD Cowen dropped their price objective on DexCom from $84.00 to $75.00 and set a “buy” rating on the stock in a report on Friday, May 1st. Piper Sandler reiterated an “overweight” rating on shares of DexCom in a research report on Thursday, February 5th. Finally, Canaccord Genuity Group set a $82.00 target price on shares of DexCom and gave the stock a “buy” rating in a research report on Monday, May 18th. Three investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $82.63.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.